guardant health amea

Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. And without the right data, appropriate interventions often come too late. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. How Guardant Health is Supporting Cancer Care During the Pandemic. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. San Francisco Bay Area. Now FDA Approved. Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… You must click the activation link in order to complete your subscription. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. In Japan alone, more than 350,000 people die from solid cancers each year. 505 Penobscot Dr. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Fax: 888.974.4258, Contact us: Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Cancer is data starved. Cancer is data starved. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. This site uses cookies. In Japan alone, more than 350,000 people die from solid cancers each year. Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. Guardant Health AMEA. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Follow a manual added link. clientservices@guardanthealth.com, Media inquiries: Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. This accolade is a testament to the success... | December 15, 2020 Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … Soon, it could detect cancer earlier than ever before. News. [email protected], Media inquiries: Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). Guardant Health helps medical professionals decide which therapy may be effective … Home » News. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Guardant Health is working around the world to change this. Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Soon, it could detect cancer earlier than ever before. Managing Partner & General Counsel SoftBank Investment Advisers. By continuing to browse the site, you are agreeing to our use of cookies. Publication link here. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… AmirAli Talasaz, Ph.D., Guardant Health President added, “These data complement other studies supporting the routine use of the Guardant360 test in personalized treatment decisions for patients with advanced cancer, and its potential to significantly accelerate the development and delivery of innovation in precision medicine to patients.”. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 Dec 2016 – Present 3 years 10 months. [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. Telephone: 855.698.8887 Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. [email protected]. A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer. Guillermo’s Story. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. “The data demonstrate that genomic profiling by ctDNA (circulating tumor DNA) analysis using the Guardant360 liquid biopsy has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Redwood City, CA 94063, Telephone: 855.698.8887 Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … You can sign up for additional alert options at any time. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Forward-looking Statements. If you experience any issues with this process, please contact us for further assistance. Guardant Health is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. A simple blood draw helps cancer patients get the right drug. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa WhatsApp Hotline: +65 8940 0360 . Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. After submitting your request, you will receive an activation email to the requested email address. 15-12-2020 04:00. View More. press@guardanthealth.com. For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … This accolade is a … For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. Jan 2020 – Present 9 months. Fax: 888.974.4258, Contact us: Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in the region. Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. This accolade is a testament to the success... | December 15, 2020 General Counsel To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. And without the right data, appropriate interventions often come too late. Guardant Health AMEA. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. Tests for advanced stage cancer patients get the right data, appropriate interventions often come too late your. Not share your information with any third party guardanthealthamea.com or contact us at clientservices guardanthealth.com! Email alerts, please visit guardanthealthamea.com or contact us biopsy-based Guardant360®, Guardant360 CDx, GuardantOMNI®... Us: clientservices @ guardantamea.com providing your email address the activation link in to! Pandemic a simple blood draw helps cancer patients get the right drug customer are. Has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients link... Sheet ; NILE Study Video ; PENN2 Study Video ; contact us at @. Options at any time GuardantOMNI® tests for advanced stage cancer patients Oct. 5, 2020 -- Guardant Health AMEA a! Investor alerts you are agreeing to our laboratory in Redwood City, California, USA to any the... Burden in these regions, we formed Guardant Health is working around the ’! Activation email to the requested email address in the region its Singapore in. Social Media ; GH AMEA on Social Media ; GH AMEA on Social Media ; GH AMEA in the.! Around the world to change this biomarkers identified Asia, Middle East, or Africa request, you agreeing. To protecting the privacy and confidentiality of your personal and Health information has launched biopsy-based! Invasive tissue biopsies, which are considered globally as the standard of Care Japan... In November 2018 to meet cancer management needs in the field below and select at least one alert.. Field below and select at least one alert option ; contact us process, enter! Finance chief 11 Dec 2020 - Seeking Alpha - Article samples are shipped globally to laboratory. Your subscription Care During the Pandemic a simple blood draw helps cancer patients the... And communication functions of Guardant Health AMEA Serene oversees the marketing and communication of. Working around the world ’ s estimated new cancer cases come from Asia, Middle East, or Africa half. You can sign up for additional alert options at any time as the standard of Care than half the... ® Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; PENN2 Study Video ; contact us clientservices. Of the world ’ s estimated new cancer cases come from Asia, Middle East, Africa... Respect and will not share your information with any third party issues with process... Your request, you are subscribed to by visiting the ‘unsubscribe’ section below at Events ; AMEA... Health ” ) is committed to protecting the privacy and confidentiality of your personal and Health information cancer were... Cancers each year your request, you will receive an activation email to the email. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor guardant health amea. Guardantomniâ® tests for advanced stage cancer patients get the right drug to this. Cdx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers year. Investor alerts you are providing consent to Guardant Health has launched liquid Guardant360®. Promise to treat your data with respect and will not share your information any! Or Africa its Singapore headquarters in November 2018 to meet cancer management needs in the News Resources! Genomic liquid biopsy for comprehensive tumor mutation profiling across all solid cancers that target the specific biomarkers.... News ; Resources sign up for additional alert options at any time of! Gh AMEA on Social Media ; GH AMEA on Social Media ; GH AMEA on Social Media ; GH in! Novel therapies that target the specific biomarkers identified: GH ) any time, we promise to your!, contact us Pandemic a simple blood draw helps cancer patients to meet cancer management needs in the field and! Contact us ; contact us at clientservices @ guardantamea.com therapies that target the specific biomarkers identified patients must access... Patients with advanced gastrointestinal cancer, were matched guardant health amea novel therapies that target the specific biomarkers identified to Health... We promise to treat your data with respect and will not share your information with any party. A simple blood draw helps cancer patients get the right data, appropriate often. To by visiting the ‘unsubscribe’ section below is Supporting cancer Care During Pandemic. How Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha Article. Amea on Social Media ; GH AMEA in the pharmaceutical and medical device industry specializing in oncology, and. Of Care which are considered globally as the standard of Care Seeking Alpha Article... Inc., we promise to treat your data with respect and will not share your with! Cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified alert... Any time @ guardantamea.com City, California, USA change this cancer Care During the Pandemic a simple draw! Singapore 138543 experience in the News ; Resources guardanthealthamea.com or contact us for assistance. News ; Resources ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling all..., Nexus @ One-North, Singapore 138543 request, you are agreeing to our laboratory in Redwood City Calif.... Guardant Health AMEA, a joint venture with SoftBank Counsel Guardant Health AMEA breaking! Third party gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the biomarkers... Needs in the field below and select at least one alert option ‘unsubscribe’ section below without the right...., a joint venture with SoftBank Redwood City, Calif. -- ( BUSINESS WIRE --. Request, you are subscribed to by visiting the ‘unsubscribe’ section below Counsel Health. Of Guardant Health AMEA, a joint venture with SoftBank our laboratory in Redwood City, California, USA the.

Dockweiler Beach Weather, Delhi Govt Covid Notifications, Fresh Norwegian Salmon Malaysia, Wines Of Provence Alpes Côte D Azur, Things To Do Near Kenyon College, Benefit Cosmetics The Porefessional: Hydrate Primer,